Lantern Pharma is a clinical stage pharmaceutical company that is revolutionizing the field of oncology. They are pioneering the use of Artificial Intelligence, Machine Learning, and genomics to develop targeted cancer therapies.
Their unique approach involves the use of a proprietary AI platform, known as RADR®, which includes more than 25 billion data points. This platform uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response. This allows Lantern Pharma to identify the cancer patients who may benefit most from their compounds.
In addition to developing new drugs, Lantern Pharma also rescues and revitalizes abandoned or failed cancer drugs using machine learning techniques and genomic data. Their current portfolio consists of three lead drug candidates and an ADC program across 12 cancer indications, including one lead product candidate in phase 2 clinical testing and recently initiated phase 1 clinical programs for two additional lead product candidates.
Lantern Pharma’s mission is to deliver precision oncology therapies to the right cancer patients with significantly reduced costs and timelines. They are transforming the cost, pace, and timeline of oncology drug discovery and development, making them a leader in the field.